Success Metrics

Clinical Success Rate
100.0%

Based on 17 completed trials

Completion Rate
100%(17/17)
Active Trials
9(32%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
10
36%
Ph phase_2
2
7%
Ph phase_3
16
57%

Phase Distribution

10

Early Stage

2

Mid Stage

16

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
10(35.7%)
Phase 2Efficacy & side effects
2(7.1%)
Phase 3Large-scale testing
16(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

17 of 17 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

28

all time

Status Distribution
Active(11)
Completed(17)

Detailed Status

Completed17
Active, not recruiting6
Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
28
Active
9
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (35.7%)
Phase 22 (7.1%)
Phase 316 (57.1%)

Trials by Status

recruiting311%
not_yet_recruiting27%
active_not_recruiting621%
completed1761%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT06388187Phase 3

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Completed
NCT05567796Phase 3

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Active Not Recruiting
NCT06534411Phase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Active Not Recruiting
NCT07557953Phase 1

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Not Yet Recruiting
NCT06221969Phase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Completed
NCT07220759Phase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Active Not Recruiting
NCT07527195Phase 1

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

Not Yet Recruiting
NCT07411560Phase 1

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Recruiting
NCT07220642Phase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Active Not Recruiting
NCT06323174Phase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Completed
NCT07253285Phase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Recruiting
NCT06131372Phase 2

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Completed
NCT05669755Phase 3

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Active Not Recruiting
NCT06409130Phase 2

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Completed
NCT06403761Phase 1

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Completed
NCT06131437Phase 3

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Completed
NCT05394519Phase 3

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Completed
NCT06065540Phase 3

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Completed
NCT05813925Phase 3

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Completed
NCT06780449Phase 3

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
28